Obstet Gynecol Sci.  2019 Mar;62(2):127-133. 10.5468/ogs.2019.62.2.127.

Positive culture rate and antimicrobial susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum

• Jang YS
• Min JW
• Kim YS

• KMID: 2471685
• DOI: http://doi.org/10.5468/ogs.2019.62.2.127

Abstract

OBJECTIVE
To assess positive culture rate and antimicrobial susceptibilities of Mycoplasma hominis (MH) and Ureaplasma urealyticum (UU) in symptomatic general population and pregnant women admitted with preterm labor and premature rupture of membranes.
METHODS
We retrospectively reviewed medical records of patients who have undergone culture test and antimicrobial susceptibilities at our center from January 2017 to April 2018. Patients with positive culture for MH, UU, or both were included in this study.
RESULTS
There were 200 patients who were eligible for enrollment. Of these patients, 34 (17%) were pregnant women and 166 (83%) were non-pregnant women. Of these 200 patients, positive culture results were as follows: MH only, n=10 (5%); UU only, n=58 (29%); and both MH and UU, n=36 (18%). Susceptibilities of MH only to doxycycline, erythromycin, ciprofloxacin, and azithromycin were 100%, 10%, 40%, and 0%, respectively. Susceptibilities of UU only to doxycycline, erythromycin, ciprofloxacin, and azithromycin were 94.8%, 87.9%, 5.2%, and 81%, respectively. Susceptibilities of both MH and UU to doxycycline, erythromycin, ciprofloxacin, and azithromycin were 97.2%, 5.6%, 11.1%, and 11.1%, respectively.
CONCLUSION
UU only was the leading causative pathogen for genitourinary infection in our study. MH only accounted for about one sixth of UU only infections. Doxycycline was still the best antibiotics as most patients with MH only, UU only, or both MH and UU positive culture showed susceptibility. For ciprofloxacin, less than 12% of those with UU only and both MH and UU culture positive results showed susceptibility.

Keyword

Mycoplasma hominis; Ureaplasma urealyticum; Culture rate; Antimicrobial susceptibility; Pregnancy

MeSH Terms

Anti-Bacterial Agents
Azithromycin
Ciprofloxacin
Doxycycline
Erythromycin
Female
Humans
Medical Records
Membranes
Mycoplasma hominis*
Mycoplasma*
Obstetric Labor, Premature
Pregnancy
Pregnant Women
Retrospective Studies
Rupture
Ureaplasma urealyticum*
Ureaplasma*
Anti-Bacterial Agents
Azithromycin
Ciprofloxacin
Doxycycline
Erythromycin

Reference

1. Kilic D, Basar MM, Kaygusuz S, Yilmaz E, Basar H, Batislam E. Prevalence and treatment of Chlamydia trachomatis, Ureaplasma urealyticum, and Mycoplasma hominis in patients with non-gonococcal urethritis. Jpn J Infect Dis. 2004; 57:17–20.

2. Krohn MA, Hillier SL, Nugent RP, Cotch MF, Carey JC, Gibbs RS, et al. The genital flora of women with intraamniotic infection. J Infect Dis. 1995; 171:1475–1480.

3. Koch A, Bilina A, Teodorowicz L, Stary A. Mycoplasma hominis and Ureaplasma urealyticum in patients with sexually transmitted diseases. Wien Klin Wochenschr. 1997; 109:584–589.

4. McDonald HM, O'Loughlin JA, Jolley PT, Vigneswaran R, McDonald PJ. Changes in vaginal flora during pregnancy and association with preterm birth. J Infect Dis. 1994; 170:724–728.

5. Waites KB, Rudd PT, Crouse DT, Canupp KC, Nelson KG, Ramsey C, et al. Chronic Ureaplasma urealyticum and Mycoplasma hominis infections of central nervous system in preterm infants. Lancet. 1988; 1:17–21.

6. Arai S, Gohara Y, Kuwano K, Kawashima T. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae. Antimicrob Agents Chemother. 1992; 36:1322–1324.

7. Hannan PC. Comparative susceptibilities of various AIDS-associated and human urogenital tract mycoplasmas and strains of Mycoplasma pneumoniae to 10 classes of antimicrobial agent in vitro . J Med Microbiol. 1998; 47:1115–1122.

8. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273. Antimicrob Agents Chemother. 1991; 35:1515–1516.

9. Ye Y, Tu S, Li H. Clinic intervention study on urogenital mycoplasma infection of pregnant women. Zhonghua Liu Xing Bing Xue Za Zhi. 2001; 22:293–295.

10. Ullmann U, Schubert S, Krausse R. Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis . J Antimicrob Chemother. 1999; 43:Suppl C. 33–36.

11. Lister PJ, Balechandran T, Ridgway GL, Robinson AJ. Comparison of azithromycin and doxycycline in the treatment of non-gonococcal urethritis in men. J Antimicrob Chemother. 1993; 31:Suppl E. 185–192.

12. Romanowski B, Talbot H, Stadnyk M, Kowalchuk P, Bowie WR. Minocycline compared with doxycycline in the treatment of nongonococcal urethritis and mucopurulent cervicitis. Ann Intern Med. 1993; 119:16–22.

13. Stamm WE, Hicks CB, Martin DH, Leone P, Hook EW 3rd, Cooper RH, et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study. JAMA. 1995; 274:545–549.

14. Roberts MC, Kenny GE. Dissemination of the tetM tetracycline resistance determinant to Ureaplasma urealyticum . Antimicrob Agents Chemother. 1986; 29:350–352.

15. Leng Z, Riley DE, Berger RE, Krieger JN, Roberts MC. Distribution and mobility of the tetracycline resistance determinant tetQ. J Antimicrob Chemother. 1997; 40:551–559.

16. Lee GH, Kim HJ, Park CH, Jeon YJ, Choi HJ, Lee HN, et al. Frequency of the causative organisms in PID and PHCS. Infect Chemother. 2012; 44:362–363.

17. Combaz-Söhnchen N, Kuhn A. A systematic review of Mycoplasma and Ureaplasma in urogynaecology. Geburtshilfe Frauenheilkd. 2017; 77:1299–1303.

18. Capoccia R, Greub G, Baud D. Ureaplasma urealyticum, Mycoplasma hominis and adverse pregnancy outcomes. Curr Opin Infect Dis. 2013; 26:231–240.

19. Khrianin AA, Reshetnikov OV. Is it safe to use josamycin in the obstetrics practice in Russia? Antibiot Khimioter. 2007; 52:32–36.

20. Whalley PJ, Adams RH, Combes B. Tetracycline toxicity in pregnancy. Liver and pancreatic dysfunction. JAMA. 1964; 189:357–362.

21. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer SM, Gideon PS, et al. Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Paediatr Perinat Epidemiol. 2009; 23:18–28.

22. Horne HW Jr, Kundsin RB. The role of mycoplasma among 81 consecutive pregnancies: a prospective study. Int J Fertil. 1980; 25:315–317.

23. Wasiela M, Krzemiński Z, Hanke W, Kalinka J. Association between genital mycoplasmas and risk of preterm delivery. Med Wieku Rozwoj. 2003; 7:Suppl 1. 211–216.

24. Park JK, Shin JK, Choi W, Lee SA, Lee JH, Paik WY. Mycoplasma infection of cervicovaginal fluid in women with preterm labor. Korean J Perinatol. 2005; 16:128–136.

25. Koh E, Kim S, Kim IS, Maeng KY, Lee SA. Antimicrobial Susceptibilities of Ureaplasma urealyticum and Mycoplasma hominis in Pregnant Women. Korean J Clin Microbiol. 2009; 12:159–162.

26. Kim SY, Lee YJ, Huh M, Lee SH, Park IY, Ahn HY, et al. Analysis of Mycoplasma hominis and Ureaplasma urealyticum infection in preterm labor and PROM patients. Korean J Obstet Gynecol. 2004; 47:1469–1473.

27. Kwak DW, Hwang HS, Kwon JY, Park YW, Kim YH. Co-infection with vaginal Ureaplasma urealyticum and Mycoplasma hominis increases adverse pregnancy outcomes in patients with preterm labor or preterm premature rupture of membranes. J Matern Fetal Neonatal Med. 2014; 27:333–337.

28. Kwon OJ, Lim YK, Oh SM, Kim TH, Choi HS, Lee SJ. Prevalence and antimicrobial susceptibility of Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum in individuals with or without symptoms of genitourinary infections. Lab Med Online. 2016; 6:79–87.

29. Lee HH, Ju KS, Lee KH, Won NH. Detection of Chlamydia trachomatis, Mycoplasma hominis and Ureaplasam urealyticum in the cervical swab and paraffin tissue with female genital tract infection. Korean J Obstet Gynecol. 1999; 42:549–555.